

CORRECTION

Correction: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study

Sarah Djabarouti^{*1}, Dominique Breilh¹, Pierre Duffau², Estibaliz Lazaro², Carine Greib², Olivier Caubet², Marie-Claude Saux¹, Jean-Luc Pellegrin² and Jean-François Viillard²

See related research by Djabarouti *et al.*, <http://arthritis-research.com/content/12/6/R217>

After publication of our recent article [1], we noticed an error in the unit for the area under the time-concentration curve between 0 and 12 hours (AUC_{0-12h}). Throughout the article and table 1 the unit should be $mg \cdot h/L$ (mg multiplied by hour per L) not $mg/hour/L$.

The correct table is given here as Table 1.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Laboratoire de Pharmacocinétique et Pharmacie Clinique EA2968, Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue de Magellan, 33604 Pessac Cedex, France. ²Service de Médecine Interne et des Maladies Infectieuses, Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue de Magellan, 33604 Pessac Cedex, France.

Published: 3 March 2011

Reference

1. Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, Saux MC, Pellegrin JL, Viillard JF: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. *Arthritis Res Ther* 2010, **12**:R217

doi:10.1186/ar3265

Cite this article as: Djabarouti S, *et al.*: Correction: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. *Arthritis Research & Therapy* 2011, **13**:401.

*Correspondence: sarah.djabarouti@chu-bordeaux.fr

¹Laboratoire de Pharmacocinétique et Pharmacie Clinique EA2968, Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue de Magellan, 33604 Pessac Cedex, France

Full list of author information is available at the end of the article

Table 1. Inclusion characteristics (of the 26 systemic lupus erythematosus patients) and their ability to predict clinical outcome (univariate analysis)

Inclusion characteristic	Total n = 26	Successes n = 17	Failures n = 8	P value ^a
Demographic				
Females/Males, number	16/10	12/5	4/4	0.28 ^b
Age, years	46 (35-61) ^a	46.5 (35-61)	46 (38-61)	0.9
Body weight, kg	60 (56-75)	60 (56-75)	62 (58-82.5)	0.62
Disease				
Duration before entry, months	11 (7-14)	11 (7-12)	10 (6-13)	0.30
SLEDAI score	0 (0-2)	0 (0-2)	0 (0-2)	0.20
C3, g/L	1 (0.6-1.1)	1 (0.9-1.1)	0.8 (0.56-0.96)	0.21
C4, g/L	0.2 (0.1-0.2)	0.2 (0.1-0.2)	0.2 (0.16-0.24)	0.78
Anti-double-stranded DNA, IU/mL	24 (6-51)	8 (1 -32)	38 (9 -55)	0.19
Biological				
GFR, mL/minute	95 (67-125)	95 (67-125)	93.5 (76-109)	0.64
Albumin, g/L	40 (39.8-43.8)	40 (37.9-43.8)	42.8 (40-46.9)	0.33
Aspartate aminotransferase, IU/L	23 (19-26)	23 (17.5-24.5)	28 (20-33)	0.26
Alanine aminotransferase, IU/L	22 (15-29)	19 (13-24.5)	25 (19-37)	0.21
γ-Glutamyltransferase, IU/L	24 (17-63)	23 (17-21)	42 (17-61)	0.92
Treatment				
MMF, g/day	2 (2-2)	2 (2-2)	2 (2-2)	0.9
Corticosteroids, mg/day	11 (7-35)	10 (5-20)	15 (7-45)	0.37
Months of MMF therapy	2 (1-3)	2 (1-3)	2 (1-3)	0.56
Months of corticosteroids	10 (6-13)	10 (5-15)	9 (5-14)	0.12
MPA pharmacokinetic parameters				
AUC _{0-12h} , mg-hour/L	64.7 (38.2-82)	73.1 (61.8-95)	37.7 (32-43.7)	0.003
C _{max} , mg/L	16.1 (9.5-18.5)	16.3 (9.7-17.4)	13.3 (7-22.5)	0.69
T _{max} , hours	1 (1-2)	1 (1-2)	1.1 (1-2)	0.82
C _{12h} , mg/L	2.4 (1.5-4.1)	3.7 (2.3-4.9)	1.5 (0.6-2.1)	0.008
MPAG pharmacokinetic parameters				
AUC _{0-12h} , mg-hour/L	775.3 (475-1,026)	791 (635-1,166)	678.8 (426-840.6)	0.22
T _{max} , hours	2 (2-3)	2.3 (2-3)	1.3 (1-2)	0.01
C _{12h} , mg/L	32.1 (24.3-41.9)	34.7 (26.4-49.2)	29.8 (15.5-40)	0.26
MPAG/MPA AUC _{0-12h} ratio	11.5 (8.3-20.7)	10.9 (6.2-14.8)	18.7 (14.1-22.7)	0.07
MPAG/MPA C _{12h} ratio	11.5 (6.8-17.3)	10.2 (6.3-15)	18.7 (11.5-47.2)	0.02

Values are expressed as median (interquartile range) unless stated otherwise. ^aMann-Whitney U test; ^bFisher exact test. AUC_{0-12h}, area under the plasma concentration-versus-time curves for hours 0 to 12; C_{12h}, 12-hour trough concentration; C_{max}, maximal concentration; GFR, glomerular filtration rate (estimated with the Cockcroft-Gault formula); MMF, mycophenolate mofetil; MPA, mycophenolic acid; MPAG, mycophenolic acid glucuronide; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; T_{max}, time to maximal concentration.